Novavax, Inc. Share Price

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 14/06/2024 BST 5-day change 1st Jan Change
14.4 USD -4.32% Intraday chart for Novavax, Inc. -20.75% +200.00%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 987M 77.82B Sales 2025 * 583M 45.94B Capitalization 2.02B 159B
Net income 2024 * 68M 5.36B Net income 2025 * -75M -5.91B EV / Sales 2024 * 1.2 x
Net cash position 2024 * 837M 66.03B Net cash position 2025 * 704M 55.54B EV / Sales 2025 * 2.26 x
P/E ratio 2024 *
34 x
P/E ratio 2025 *
-44.3 x
Employees 1,543
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.14%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.32%
1 week-20.75%
Current month-4.19%
1 month+6.82%
3 months+189.16%
6 months+153.08%
Current year+200.00%
More quotes
1 week
13.50
Extreme 13.5
17.86
1 month
12.03
Extreme 12.03
23.86
Current year
3.53
Extreme 3.5324
23.86
1 year
3.53
Extreme 3.5324
23.86
3 years
3.53
Extreme 3.5324
277.80
5 years
3.53
Extreme 3.5324
331.68
10 years
3.53
Extreme 3.5324
331.68
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 22/01/23
President 64 09/03/14
Director of Finance/CFO 58 15/08/21
Members of the board TitleAgeSince
Director/Board Member 57 28/10/22
Director/Board Member 58 31/10/20
Director/Board Member 58 15/06/20
More insiders
Date Price Change Volume
14/06/24 14.4 -4.32% 17,326,785
13/06/24 15.05 -5.11% 9,378,558
12/06/24 15.86 -5.17% 11,200,788
11/06/24 16.72 +4.50% 13,864,003
10/06/24 16 -11.92% 19,363,144

Delayed Quote Nasdaq, June 14, 2024 at 09:00 pm

More quotes
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
14.4 USD
Average target price
22.8 USD
Spread / Average Target
+58.33%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW